VEGFA and acute myeloid leukemia: Based on the results of clinical trials, some antiangiogenic drugs that inhibit vascular endothelial growth factor (VEGF), such as bevacizumab (Karp et al., 2004), cediranib (Fiedler et al., 2010), AG-013736 (Giles et al., 2006), and SU5416 (Fiedler et al., 2003), could be an effective treatment for AML, either alone or in addition to chemotherapy that works independently on different targets.